RESUMEN
Posterior reversible encephalopathy syndrome is a neurotoxic state accompanied by unique brain imaging patterns and neurologic abnormalities, typically associated with several complex clinical conditions such as preeclampsia/eclampsia, solid-organ transplant procedures, autoimmune diseases, and immunosuppressive agents. The detailed mechanism of posterior reversible encephalopathy syndrome is not known, and the current therapy is only supportive care. Here, we present a 33-year-old parturient woman with preeclampsia complicated with hemolysis, elevated liver enzymes, and low platelet syndrome, fulminant hepatitis B, acute fatty liver, and posterior reversible encephalopathy syndrome. The patient developed gross hepatic infarction soon after liver transplant. After several possible causes were excluded, we found that progression of underlying posterior reversible encephalopathy syndrome-induced endothelial damage by overdose of tacrolimus may have been the major cause for deteriorating hypoperfusion of the transplanted liver and fatal graft failure. In liver transplant recipients, severe posttransplant hypoperfusion of the grafted liver may result in loss of the liver allograft and even mortality. Poor control of underlying posterior reversible encephalopathy syndrome-associated endothelial damage because of tacrolimus overdose may lead to severe hypoperfusion of grafted hepatic vessels and subsequent hepatic infarction. This report highlights tacrolimus as a potential trigger of posterior reversible encephalopathy syndrome and may inform clinical decisions regarding tacrolimus administration in liver transplant recipients with preexisting or newly developed posterior reversible encephalopathy syndrome.
Asunto(s)
Inhibidores de la Calcineurina/envenenamiento , Infarto Hepático/inducido químicamente , Inmunosupresores/envenenamiento , Trasplante de Hígado/efectos adversos , Síndrome de Leucoencefalopatía Posterior/inducido químicamente , Tacrolimus/envenenamiento , Adulto , Inhibidores de la Calcineurina/administración & dosificación , Progresión de la Enfermedad , Sobredosis de Droga , Resultado Fatal , Femenino , Infarto Hepático/diagnóstico por imagen , Infarto Hepático/terapia , Humanos , Inmunosupresores/administración & dosificación , Donadores Vivos , Insuficiencia Multiorgánica/etiología , Síndrome de Leucoencefalopatía Posterior/diagnóstico por imagen , Síndrome de Leucoencefalopatía Posterior/terapia , Embarazo , Tacrolimus/administración & dosificaciónRESUMEN
BACKGROUND: Selection of expected phenotypes (ie, expressers/non-expressers) is currently used in CYP3A5*3 genotype-based tacrolimus dosing. The authors assessed whether a dosing regimen based on the 3 CYP3A5 genotypes may reduce the occurrence of inadequate exposure. METHODS: Tacrolimus whole blood trough levels (C0) were retrieved from a retrospective cohort of 100 kidney transplant recipients treated with a starting dose of 0.15 (non-expressers) or 0.30 (expressers) mg/kg/d. The authors evaluated the occurrence of overexposures (12 < C0 < 20 ng/mL) or toxic concentrations (C0 ≥ 20 ng/mL). These results were used to set up a new strategy based on the 3 distinct CYP3A5 genotypes, which relevance was evaluated in a prospective cohort of 107 patients. RESULTS: In the retrospective cohort, non-expressers exhibited frequent overexposure (63.6%) or toxic C0 (20.8%). Among expressers, none of the homozygous *1 carriers exhibited overexposure contrary to 25% of the heterozygotes. Based on these results, new tacrolimus starting doses were set at 0.10, 0.20, and 0.30 mg/kg/d for CYP3A5*3/*3, CYP3A5*1/*3, and CYP3A5*1/*1 genotypes, respectively. Tacrolimus overexposure was reduced in the CYP3A5*3/*3 group (63.6% vs 40%, P = .0038). None of the heterozygous patients exhibited toxic tacrolimus C0. Clinical outcomes were not different between the 2 periods, whatever the genotype. Our results indicate that the best tacrolimus exposure was obtained for doses of 0.10, 0.20, and 0.20 mg/kg/d for CYP3A5*3/3, CYP3A5*1/*3, and CYP3A5*1/*1, respectively. CONCLUSIONS: Our results confirm that selecting tacrolimus dosing regimen according to the expected phenotype is appropriate, but that lower than currently recommended doses may be preferable.
Asunto(s)
Citocromo P-450 CYP3A/genética , Rechazo de Injerto/prevención & control , Inmunosupresores/administración & dosificación , Trasplante de Riñón , Tacrolimus/administración & dosificación , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Citocromo P-450 CYP3A/metabolismo , Femenino , Genotipo , Humanos , Inmunosupresores/metabolismo , Inmunosupresores/envenenamiento , Masculino , Persona de Mediana Edad , Pruebas de Farmacogenómica , Fenotipo , Estudios Prospectivos , Estudios Retrospectivos , Tacrolimus/metabolismo , Tacrolimus/envenenamiento , Adulto JovenRESUMEN
BACKGROUND: Data is limited on comparison of acute and chronic methotrexate (MTX) poisoning. Methotrexate is an anti-folate drug that may be prescribed in some malignant or chronic inflammatory conditions. The aim of the current study was to compare signs and symptoms, complications, treatment and final outcome of acute and chronic MTX toxicity. METHOD: In a retrospective study in a referral center between March 2010 and March 2018, all patients who had been referred with the history of MTX poisoning and hospitalized due to acute or chronic poisoning were evaluated and compared. RESULTS: Of the total 27 patients admitted during the study period, 13 had referred with acute (group 1; consumption of MTX for less than 7 days) and 14 had referred with chronic toxicity (group 2; consumption of MTX for more than 7 days). Mean age was significantly higher in the second group (P < 0.001). Median total dose of MTX was similar between the groups (P = 0.90). Mucosal ulcers and skin lesions (P < 0.001 and 0.02, respectively) were the only symptoms significantly different between the two groups. Leukopenia (P < 0.001), thrombocytopenia (P < 0.001), and anemia (P = 0.04) were significantly more common in the second group. Blood urea nitrogen and creatinine were also significantly higher in the second group of the patients (P < 0.001 and P = 0.048). Median leucovorin administered dose was 200 mg [14, 480] versus 150 mg [75, 187] (P = 0.69) in groups 1 and 2, respectively. CONCLUSIONS: Chronic MTX poisoning is more serious than acute toxicity and accompanies higher dermatologic, hematologic, and hepatic complications necessitating more aggressive treatments including administration of higher doses of leucovorin or bone marrow stimulants such as G-CSF. This may be attributable to the underlying diseases and features (including older ages) which predispose these patients to complications.
Asunto(s)
Antimetabolitos Antineoplásicos/envenenamiento , Antagonistas del Ácido Fólico/envenenamiento , Inmunosupresores/envenenamiento , Metotrexato/envenenamiento , Enfermedad Aguda , Adolescente , Adulto , Anciano , Niño , Preescolar , Enfermedad Crónica , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Adulto JovenRESUMEN
INTRODUCTION: Fingolimod is an immunomodulating agent used in multiple sclerosis (MS). It is a sphingosine-1-phosphate (S1P) receptor agonist prescribed for relapsing forms of MS to delay onset of physical disability. As fingolimod is known to cause first-dose bradycardia, telemetry is recommended for the first 6 h post-dose. We present the first reported case of deliberate fingolimod overdose requiring atropine administration for bradycardia and hemodynamic instability. CASE REPORT: A 33-year-old woman ingested 14 mg of fingolimod and 2 g of phenoxymethylpenicillin. After presenting to the emergency department 19 h later, she was initially hemodynamically stable (heart rate (HR) 60, blood pressure (BP) 113/89 mmHg). Two hours later, she then developed bradycardia (HR 48) and hypotension (87/57 mmHg). Despite intravenous fluids, stabilisation was only achieved after administration of atropine (300 µg). She was then admitted to the intensive care unit (ICU) for further monitoring where another episode of bradycardia and hypotension required atropine. She was monitored in the ICU for 48 h and then discharged on day 5 with no further episodes. DISCUSSION: Fingolimod is known to cause bradycardia in the first 6 h post first therapeutic dose. Following intentional overdose, onset of bradycardia occurred at 21 h post-ingestion and was associated with hypotension. Atropine was successful in treating bradycardia and associated hypotension.
Asunto(s)
Atropina/uso terapéutico , Bradicardia/tratamiento farmacológico , Sobredosis de Droga/terapia , Hipotensión/tratamiento farmacológico , Inmunosupresores/envenenamiento , Antagonistas Muscarínicos/uso terapéutico , Glicoles de Propileno/envenenamiento , Esfingosina/análogos & derivados , Adulto , Antídotos/uso terapéutico , Bradicardia/etiología , Terapia Combinada/efectos adversos , Sobredosis de Droga/fisiopatología , Femenino , Clorhidrato de Fingolimod , Humanos , Hipotensión/etiología , Inmunosupresores/antagonistas & inhibidores , Glicoles de Propileno/antagonistas & inhibidores , Esfingosina/antagonistas & inhibidores , Esfingosina/envenenamiento , Factores de Tiempo , Resultado del TratamientoRESUMEN
A 14-year-old girl with systemic lupus erythematosus presented with a mixed overdose of paracetamol, ibuprofen and azathioprine (1500 mg) following a deliberate self-harm attempt. The patient was admitted and monitored. No adverse effects were observed. A review of the literature showed very few reported azathioprine overdoses. Lupus patients are at risk of developing low mood and depression (and related self-harm including overdose of medication). This can be as a consequence of the disease process itself or in reaction to the stresses of living with a chronic disease, which are perhaps particularly acute in some adolescents with the disease. An intentional overdose in a patient with lupus is clearly a cry for help and should be appropriately managed. Counselling of young people and their parents about possible mood disorders is an important part of the management of this chronic disease. Despite the theoretical risk of significant myelosuppression as well as other potential adverse effects, azathioprine in acute overdose seems to be generally well tolerated.
Asunto(s)
Antidepresivos/uso terapéutico , Azatioprina/envenenamiento , Depresión/tratamiento farmacológico , Sobredosis de Droga , Inmunosupresores/envenenamiento , Lupus Eritematoso Sistémico/tratamiento farmacológico , Intento de Suicidio , Acetaminofén/envenenamiento , Adolescente , Trastornos Psicóticos Afectivos/tratamiento farmacológico , Trastornos Psicóticos Afectivos/rehabilitación , Antiinflamatorios no Esteroideos/envenenamiento , Depresión/etiología , Consejo Dirigido , Femenino , Hospitalización , Humanos , Ibuprofeno/envenenamiento , Lupus Eritematoso Sistémico/psicología , Padres , Resultado del TratamientoRESUMEN
Transplant recipients and other patients requiring immunosuppression with calcineurin inhibitors or their household contacts may be exposed to overdose. This study investigated the circumstances, pharmacokinetics and outcomes of overdose with cyclosporine and tacrolimus reported to the Swiss Toxicological Information Centre between 1995 and 2011. Of 145,396 reports by healthcare professionals, 28 (0.02%) concerned enteral or parenteral overdose with these calcineurin inhibitors. Thirteen (46%) were iatrogenic errors, 12 (43%) were with suicidal intent and 3 (11%) were accidental. Iatrogenic overdoses usually involved noncapsule drug formulations. Acute enteral overdoses caused symptoms in a dose-dependent fashion but were generally well tolerated; the mean multiple of patient's usual dose was 20.8 ± 28.8 for symptomatic versus 4.4 ± 3.4 for asymptomatic cases (p = 0.037). The most common symptoms were nausea, headache, somnolence, confusion, hypertension and renal impairment. In contrast, acute intravenous overdoses were often poorly tolerated and resulted in one fatality due to cerebral edema after a cyclosporine overdose. Enteral decontamination measures were performed in six cases involving oral ingestion and appeared to reduce drug absorption, as shown by pharmacokinetic calculations. In the one case where it was used, pharmacoenhancement appeared to accelerate tacrolimus clearance after intravenous overdose.
Asunto(s)
Inhibidores de la Calcineurina , Ciclosporina/envenenamiento , Sobredosis de Droga/epidemiología , Rechazo de Injerto/tratamiento farmacológico , Inmunosupresores/envenenamiento , Tacrolimus/envenenamiento , Enfermedad Aguda , Adolescente , Adulto , Anciano , Atención Ambulatoria , Niño , Preescolar , Ciclosporina/farmacocinética , Descontaminación , Femenino , Estudios de Seguimiento , Rechazo de Injerto/etiología , Humanos , Inmunosupresores/farmacocinética , Lactante , Masculino , Persona de Mediana Edad , Centros de Control de Intoxicaciones , Pronóstico , Estudios Retrospectivos , Factores de Riesgo , Suiza/epidemiología , Tacrolimus/farmacocinética , Factores de Tiempo , Distribución Tisular , Adulto JovenRESUMEN
Copper is an essential trace element for human physiological processes. To evaluate the potential adverse health impact/immunotoxicological effects of this metal in situ due to over exposure, Swiss albino mice were treated (via intraperitoneal injections) with copper (II) chloride (copper chloride) at doses of 0, 5, or 7.5 mg copper chloride/kg body weight (b.w.) twice a week for 4 wk; these values were derived from LD50 studies using copper chloride doses that ranged from 0 to 40 mg/kg BW (2×/wk, for 4 wk). Copper treated mice evidenced immunotoxicity as indicated by dose-related decreases and increases, respectively, in thymic and splenic weights. Histomorphological changes evidenced in these organs were thymic atrophy, white pulp shrinkage in the spleen, and apoptosis of splenocytes and thymocytes; these observations were confirmed by microscopic analyses. Cell count analyses indicated that the proliferative functions of the splenocytes and thymocytes were also altered because of the copper exposures. Among both cell types from the copper treated hosts, flow cytometric analyses revealed a dose related increase in the percentages of cells in the Sub-G0/G1 state, indicative of apoptosis which was further confirmed by Annexin V binding assay. In addition, the copper treatments altered the expression of selected cell death related genes such as EndoG and Bax in a dose related manner. Immunohistochemical analyses revealed that there was also increased ubiquitin expression in both the cell types. In conclusion, these studies show that sublethal exposure to copper (as copper chloride) induces toxicity in the thymus and spleen, and increased Sub G0/G1 population among splenocytes and thymocytes that is mediated, in part, by the EndoG-Bax-ubiquitin pathway. This latter damage to these cells that reside in critical immune system organs are likely to be important contributing factors underlying the immunosuppression that has been documented by other investigators following acute high dose/chronic low-medium dose exposures to copper agents.
Asunto(s)
Puntos de Control del Ciclo Celular/efectos de los fármacos , Muerte Celular/efectos de los fármacos , Cobre/envenenamiento , Inmunosupresores/envenenamiento , Bazo/efectos de los fármacos , Timo/efectos de los fármacos , Animales , Apoptosis/efectos de los fármacos , Atrofia/inducido químicamente , Recuento de Células , Células Cultivadas , Cobre/administración & dosificación , Relación Dosis-Respuesta a Droga , Endodesoxirribonucleasas/metabolismo , Inmunosupresores/administración & dosificación , Inyecciones Intraperitoneales , Dosificación Letal Mediana , Ratones , Tamaño de los Órganos/efectos de los fármacos , Distribución Aleatoria , Bazo/inmunología , Bazo/metabolismo , Bazo/patología , Timo/inmunología , Timo/metabolismo , Timo/patología , Ubiquitina/metabolismo , Proteína X Asociada a bcl-2/metabolismoRESUMEN
INTRODUCTION: Tacrolimus is an immunosuppressant widely used in recipients of solid organ transplants to prevent rejection. Toxicity is usually reported in transplant patients. We report the first case of tacrolimus toxicity in a non-transplant patient. CASE REPORT: A 42 year-old, 48 kg woman complained of neck pain following a motor vehicle collision and was admitted for observation. On examination, her pulse was 112 beats/minute and her blood pressure 188/134 mmHg. Because the hypertension and tachycardia might be ethanol withdrawal, she was admitted and treated with multivitamins, folate, and thiamine in her maintenance fluids. She was discharged after 4 days in hospital. The day after her discharge, she was asked to return after it was discovered that she had inadvertently received tacrolimus (total of 400 mg) instead of thiamine. She was admitted with non-oliguric renal failure and metabolic acidosis. A tacrolimus concentration 27 hours after her last exposure was 96.8 ng/mL (therapeutic 5 to 20 ng/mL). Treatment was supportive and she was discharged after 4 days without sequellae. DISCUSSION: Our patient's tacrolimus dose was 2.1 mg/kg/day for 4 days (therapeutic 0.03 to 0.05 mg/kg/day). Her tacrolimus elimination half-life was 16.5 hours, compared to a mean half-life in healthy volunteers of 34.2 +/- 7.7 hours. CONCLUSION: Clinical toxicity, similar to that seen in transplant patients, can develop in non-transplant patients following intravenous administration of supra-therapeutic doses of tacrolimus.
Asunto(s)
Lesión Renal Aguda/inducido químicamente , Inmunosupresores/envenenamiento , Errores de Medicación , Tacrolimus/envenenamiento , Acidosis/inducido químicamente , Adulto , Femenino , Semivida , Humanos , Inmunosupresores/farmacocinética , Servicio de Farmacia en Hospital , Tacrolimus/farmacocinética , Tiamina/uso terapéuticoAsunto(s)
Equimosis/inducido químicamente , Inmunosupresores/envenenamiento , Síndrome Nefrótico/tratamiento farmacológico , Tacrolimus/envenenamiento , Enfermedad Aguda , Preescolar , Sobredosis de Droga , Femenino , Humanos , Inmunosupresores/administración & dosificación , Recurrencia , Tacrolimus/administración & dosificaciónAsunto(s)
Inmunosupresores/envenenamiento , Ácido Micofenólico/análogos & derivados , Adolescente , Femenino , Granulomatosis con Poliangitis/tratamiento farmacológico , Humanos , Inmunosupresores/uso terapéutico , Ácido Micofenólico/envenenamiento , Ácido Micofenólico/uso terapéutico , Intento de SuicidioRESUMEN
Acute cyclosporine A (CsA) intoxication after organ transplantation may occur during the changeover from one form of drug to another, or from miscalculation of dosage. Sometimes, it may cause severe hepatotoxicity, nephrotoxicity and neurotoxicity. However, the therapeutic plasma exchange for the CsA intoxication was not established. Here, we present a case of very severe CsA intoxication after cardiac transplantation who recovered from intoxication without long-term sequelae via whole blood exchange; therapeutic erythrocytapheresis followed by total plasma exchange.
Asunto(s)
Eliminación de Componentes Sanguíneos , Ciclosporina/envenenamiento , Sobredosis de Droga/terapia , Recambio Total de Sangre/métodos , Inmunosupresores/envenenamiento , Transfusión de Eritrocitos , Trasplante de Corazón , Humanos , Masculino , Persona de Mediana Edad , Intercambio PlasmáticoRESUMEN
A case of a 23-year-old female, after renal transplant, who had tried to commit suicide with 100 mg of Prograf was described. In the presented case despite the relatively high tacrolimus blood concentration level (>30 microg/l) only severe 5-hour lasting headache and short-term mild hyperglycaemia (7.22 mmol/l), hyperkalemia (5.4 mmol/l) and considerable leukocytosis (19.52 x 10(3)) were observed. In this case there was mild clinical course of intoxication despite tacrolimus high blood concentration. It could not be excluded that early administration of gastric lavage and activated carbon was partly responsible for mild course of poisoning.
Asunto(s)
Inmunosupresores/envenenamiento , Trasplante de Riñón , Intento de Suicidio , Tacrolimus/envenenamiento , Enfermedad Aguda , Adulto , Carbón Orgánico/uso terapéutico , Depresión/etiología , Sobredosis de Droga , Femenino , Humanos , Trasplante de Riñón/psicología , Intoxicación/complicaciones , Intento de Suicidio/psicología , Factores de Tiempo , Resultado del TratamientoRESUMEN
BACKGROUND: The pathogenesis of cyclosporine A (CsA)-induced nephrotoxicity has been known to be secondary to hemodynamic changes, but increasing evidence indicates that CsA has a direct toxicity to renal tubular cells, leading to their apoptosis and tubulointerstitial fibrosis. This study evaluated the mechanism for CsA-induced tubular cell apoptosis, tubulointerstitial fibrosis and its associated proteins, and the therapeutic effects of alpha-melanocyte-stimulating hormone (MSH) on them. METHODS: Male Sprague-Dawley rats fed with a low-sodium diet were divided into three treatment groups: group A (vehicle-injected group), group B (CsA 15 mg/kg-injected group), and group C(CsA+alpha-MSH-injected group). After 42 days, creatinine clearance; blood CsA level; apoptosis; inflammation and tubulointerstitial fibrosis in renal tissue; and the expression of Bax, Bcl2, Fas, FasL, and transforming growth factor (TGF)-beta protein were determined. RESULTS: CsA-induced tubular cell apoptosis; cellular infiltration; and increase of Fas, Bax, TGF-beta protein expression with significant tubulointerstitial fibrosis, and reduced Bcl2 protein expression. alpha-MSH treatment prevented the Bax and TGF-beta protein increase and induced Bcl2 protein increase, together with reduction of apoptosis, inflammation, and tubulointerstitial fibrosis. CONCLUSIONS: These findings suggest that chronic CsA nephrotoxicity is related to Bax and Bcl2-related apoptosis pathways, and that alpha-MSH can attenuate the CsA-induced tubulointerstitial fibrosis as well as tubular cell apoptosis.
Asunto(s)
Apoptosis/efectos de los fármacos , Ciclosporina/envenenamiento , Inmunosupresores/envenenamiento , Túbulos Renales/fisiopatología , Nefritis Intersticial/inducido químicamente , Nefritis Intersticial/fisiopatología , alfa-MSH/farmacología , Animales , Antígenos de Superficie , Enfermedad Crónica , Fibrosis , Etiquetado Corte-Fin in Situ , Túbulos Renales/efectos de los fármacos , Túbulos Renales/metabolismo , Túbulos Renales/patología , Masculino , Nefritis Intersticial/metabolismo , Nefritis Intersticial/patología , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Ratas , Ratas Sprague-Dawley , Factor de Crecimiento Transformador beta/metabolismo , Proteína X Asociada a bcl-2RESUMEN
Mycophenolate mofetil is an immunosuppressive drug used for prevention of graft rejection following solid organ transplant and for treatment of autoimmune disorders. We report a case of a 24-year-old female with lupus nephritis that presented following ingestion of 10 grams of mycophenolate in a suicide gesture. Serum levels confirmed ingestion. The patient was treated with decontamination and supportive care and recovered with no adverse effect.
Asunto(s)
Inmunosupresores/envenenamiento , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/envenenamiento , Adulto , Antídotos/uso terapéutico , Recuento de Células Sanguíneas , Carbón Orgánico/uso terapéutico , Sobredosis de Droga , Femenino , Hemodinámica , Humanos , Inmunosupresores/uso terapéutico , Nefritis Lúpica/tratamiento farmacológico , Ácido Micofenólico/uso terapéutico , Intento de SuicidioRESUMEN
Neuroimaging, particularly MR imaging, plays a major role for the diagnosis of many acute toxic encephalopathies. Toxic disorders are related to drugs (immunosuppressive agents, chemotherapeutic agents, anti-epileptic drugs, heroin...), to metals (lead, manganese, mercury...), and to industrial and environmental chemicals (solvent, carbon monoxide...). MR imaging with diffusion and perfusion imaging provides information regarding brain lesions induced by the toxic agents (vasogenic edema, cytotoxic edema, infarction, hemorrhage, demyelination...).
Asunto(s)
Tratamiento de Urgencia/métodos , Neurorradiografía/métodos , Síndromes de Neurotoxicidad/diagnóstico , Enfermedad Aguda , Disuasivos de Alcohol/envenenamiento , Anticonvulsivantes/envenenamiento , Intoxicación por Monóxido de Carbono/diagnóstico , Diagnóstico Diferencial , Disulfiram/envenenamiento , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Etanol/envenenamiento , Sustancias Peligrosas/envenenamiento , Intoxicación por Metales Pesados , Humanos , Inmunosupresores/envenenamiento , Imagen por Resonancia Magnética , Metanol/envenenamiento , Metotrexato/envenenamiento , Mielinólisis Pontino Central/diagnóstico , Síndromes de Neurotoxicidad/etiología , Trastornos Relacionados con Sustancias/diagnóstico , Encefalopatía de Wernicke/diagnósticoRESUMEN
A 58-year-old man with end-stage renal failure secondary to polycystic kidney disease developed a profoundly elevated mycophenolic acid (MPA) free fraction and associated severe toxicity after cadaveric renal transplantation. Initial immunosuppressive therapy was 4 mg/kg body weight bid cyclosporin (Neoral; Novartis Pharmaceutical Co Ltd, Sydney, Australia) given orally with 1 g bid mycophenolate mofetil (MMF) (CellCept; Roche Products Pty Ltd, Sydney, Australia). In the first 5 days posttransplantation, the serum creatinine concentration fell, and the patient developed profound hypoalbuminemia (serum albumin <20 g/L) and hyperbilirubinemia (serum bilirubin >150 micromol/L) that resulted from progressing biliary obstruction. On day 5 posttransplantation, the 2-hour whole-blood cyclosporin concentration and total MPA area under the curve (AUC(0-6)) were low (837 microg/L and 12.6 mg x h/L, respectively), while the total mycophenolic acid glucuronide (MPAG) AUC(0-6) was elevated (1317 mg x h/L). MMF was continued at the same dose, but tacrolimus substituted for cyclosporin. The patient subsequently experienced severe nausea, vomiting, hematemesis, and pancytopenia (nadir white cell count 1.6 x 10(9)/L, platelet count 32 x 10(9)/L, and hemoglobin 73 g/L) that were normalized after cessation of MMF. Retrospective measurement of the free MPA concentration on day 5 showed that free MPA AUC(0-6) was markedly elevated at 2.3 mg x h/L, as was the free fraction, at 18.3%. This case illustrates how altered protein binding can be associated with severe MMF toxicity caused by an increased free MPA concentration despite relatively low total MPA. These data support the monitoring of free MPA concentrations in those patients considered at risk for MMF-related toxicity.
Asunto(s)
Inmunosupresores/envenenamiento , Trasplante de Riñón , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/sangre , Ácido Micofenólico/envenenamiento , Humanos , Inmunosupresores/metabolismo , Inmunosupresores/uso terapéutico , Masculino , Persona de Mediana Edad , Ácido Micofenólico/metabolismo , Ácido Micofenólico/uso terapéutico , Factores de TiempoRESUMEN
Cyclosporine (CsA) has improved patient and graft survival rates following solid-organ transplantation and has been increasingly applied with significant clinical benefits in the management of autoimmune diseases. However, the clinical use of CsA is often limited by acute and chronic nephrotoxicity, which remains a major problem. Acute nephrotoxicity depends on the dosage of CsA and seems to be caused by a reduction in renal blood flow related to afferent arteriolar vasoconstriction. However, the mechanisms underlying chronic CsA nephrotoxicity are not fully understood. Activation of the intrarenal renin-angiotensin system, increased release of endothelin-1, dysregulation of nitric oxide (NO) and NO synthase, upregulation of transforming growth factor-beta1, inappropriate apoptosis, stimulation of inflammatory mediators, and enhanced immunogenecity have all been implicated in the pathogenesis of chronic CsA nephrotoxicity. Reducing the CsA dose or withdrawing it and using combined nephroprotective drugs (mycophenolate mofetil, losartan, and pravastatin) may ameliorate chronic CsA-induced renal injury. This review discusses new insights and preventive strategies for this clinical dilemma.
Asunto(s)
Ciclosporina/envenenamiento , Inmunosupresores/envenenamiento , Enfermedades Renales/inducido químicamente , Enfermedades Renales/prevención & control , Trasplante de Órganos , Animales , Enfermedad Crónica , Ciclosporina/uso terapéutico , Humanos , Inmunosupresores/uso terapéuticoRESUMEN
Cyclosporine (CsA) has improved patient and graft survival rates following solid-organ transplantation and has been increasingly applied with significant clinical benefits in the management of autoimmune diseases. However, the clinical use of CsA is often limited by acute and chronic nephrotoxicity, which remains a major problem. Acute nephrotoxicity depends on the dosage of CsA and seems to be caused by a reduction in renal blood flow related to afferent arteriolar vasoconstriction. However, the mechanisms underlying chronic CsA nephrotoxicity are not fully understood. Activation of the intrarenal renin-angiotensin system, increased release of endothelin-1, dysregulation of nitric oxide (NO) and NO synthase, upregulation of transforming growth factor-beta1, inappropriate apoptosis, stimulation of inflammatory mediators, and enhanced immunogenecity have all been implicated in the pathogenesis of chronic CsA nephrotoxicity. Reducing the CsA dose or withdrawing it and using combined nephroprotective drugs (mycophenolate mofetil, losartan, and pravastatin) may ameliorate chronic CsA-induced renal injury. This review discusses new insights and preventive strategies for this clinical dilemma.